Abterra Bio News

Stay updated on all things Abterra Bio. Includes scientific and company updates.

New Service: Alicanto for Antibody Discovery from Human Serum

We recently had the pleasure of attending the PEGS Boston Conference. We had the privilege of showcasing our work through a poster presentation, a talk, and an exhibit booth. Among the highlights were engaging with experts, exchanging ideas, and strengthening our network within the community. But perhaps the most important was launching our newest service: Alicanto For Antibody Discovery From Human Serum. It was truly a great time for Abterra Biosciences!

Watch our CEO, Dr. Natalie Castellana’s presentation on Discovering SARS-CoV2 Antibodies From Patient Serum With Alicanto below. This was our first antibody discovery project utilizing human serum!

Click below to watch the presentation.


Related Posts

Abterra Bio Has Moved To Sorrento Valley

Abterra Bio Has Moved To Sorrento Valley

Abterra Bio Has Moved To Sorrento Valley In 2009, Abterra Bio began as Digital Proteomics LLC, a spin-out of the University of California – San Diego. Founders Pavel Pevzner and Vineet Bafna, as well as Natalie Castellana, Stefano Bonissone, and Anand Patel have been...

Advantages of High-Throughput Hybridoma Sequencing with NGS

Advantages of High-Throughput Hybridoma Sequencing with NGS

Having a diverse collection of leads at the beginning of your antibody development campaign is critical for downstream success. As we know well, the immune response to immunization often focuses on a small number of antibody families with highly similar CDR3s which...

Abterra Biosciences is a unique CRO offering antibody sequencing and discovery services.  We bring sophisticated algorithmic and machine learning approaches to enable accurate antibody sequencing and functional antibody discovery.

Tell Us About Your Project

Follow Abterra Bio On Social Media

More From Our Blog

Get In Touch

Tell Us About Your Project.

Need more information? We’re here to answer any questions you have.